Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search


IMV is a Canadian biopharmaceutical company focused on developing immunotherapies for serious human diseases using its proprietary lipid-based delivery system, which the company calls DPX.

IMV Inc. is a clinical-stage pharmaceutical company developing an effective T cell-targeted immune therapy for cancer. The company has built a delivery platform (DPX) that generates targeted immune cells directly into the human body, which produces robust and sustained capabilities to destroy cancer.

Its lead drug candidate, Maveropepimut-S (DPX-Survivac), which has completed multiple Phase 1/1b trials successfully, has generated positive results in advanced recurrent ovarian cancer and Diffuse Large B Cell Lymphoma (DLBCL).

IMV's DPX Platform enables antigen-presenting cells (APCs) to be attracted to the injection site, facilitating antigen presentation to immune cells. All IMV's immunotherapies and vaccines candidates are formulated with the DPX platform, giving them the ability to generate, in vivo, a targeted, robust, and sustained immune response against cancer cells or viruses.

The company is partnering with pharmaceutical companies, government agencies, and academic research institutions for the purpose of research and development.


June 9, 2021
IMV announces appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer
May 18, 2020
IMV raises a $25,100,000 private equity from Fonds de solidarité FTQ and Lumira Ventures.
March 30, 2020
IMV Inc. provides updates on the development of DPX-COVID-19 Vaccine.

According to a press release from the company, IMV has made "significant progress" in its COVID-19 vaccine development efforts.

March 18, 2020
IMV Inc. launches plans to advance clinical development of a vaccine candidate against COVID-19
March 11, 2019
IMV raises a $29,500,000 private equity from Fonds de solidarité FTQ.

Funding rounds


Further Resources



April 5, 2021
Respiratory Supports and COVID-19 Mortality - Full Text View.
Science and Medicine Group Inc
January 5, 2021
/PRNewswire/ -- The unpredictable events of 2020 might cause one to forswear all prediction-making. Yet for Science and Medicine Group's publishing brands...
November 24, 2020
Mortality in Patients With Severe COVID-19 Pneumonia Who Underwent Tracheostomy - Full Text View.


Golden logo
By using this site, you agree to our Terms & Conditions.